Biocure Technology Inc (TSE:CURE) has released an update.
Biocure Technology Inc. has announced the mutual termination of its previously planned acquisition of Atriva Therapeutics, with no penalties incurred by either party. The agreement’s conclusion comes after an inability to complete the transaction within the set timeframe. Consequently, Biocure’s halted shares are anticipated to resume trading on the Canadian Stock Exchange subject to regulatory approval.
For further insights into TSE:CURE stock, check out TipRanks’ Stock Analysis page.
